Corgenix Teams Up with Strategic Partners at AACC Clinical Lab Expo 2013

Corgenix Teams Up with Strategic Partners at AACC Clinical Lab Expo 2013

Corgenix to exhibit AspirinWorks ^® Test and SkyLAB752™ high-throughput automated platform

DENVER--(BUSINESS WIRE)-- Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners ELITech Group and AXA Diagnostics at the AACC Clinical Lab Expo 2013 in Houston, Texas.

Corgenix will exhibit its AspirinWorks^® (11dhTxB2) Test at AACC July 30 - August 1 in booth No. 3009.

Also on display in the Corgenix booth will be the SkyLAB752™ instrument from strategic partner AXA Diagnostics. The Corgenix team will present the new, high-throughput ELISA automated platform, which can process up to 7 microplates simultaneously. The SkyLAB752 is the fastest automated instrument for processing the Corgenix AspirinWorks assay, due to its ability to process up to 384 samples in a single run.

Additionally, Corgenix will have a presence in strategic partner ELITech Group's booth No. 4707 and 4805, where several Corgenix products will be on display, including the AspirinWorks/11dhTxB2 and Hyaluronic Acid Test Kits. In 2010, the two companies entered into a formal strategic alliance to co-develop new diagnostic tests. The alliance includes an ELITech Group investment in Corgenix and the expansion of Corgenix' distribution network for its test kits. The Hyaluronic Acid Test Kit has not been cleared or approved for diagnostic use in the Untied States by the US Food and Drug Administration. However, it is CE marked for diagnostic use in the EU.

Corgenix representatives will be available during the conference to answer questions about the AspirinWorks Test and other products, including its diagnostic kits for immunology disorders, vascular diseases, and bone and joint disorders.

AspirinWorks is a simple, non-invasive lab test performed on a urine specimen, which helps doctors accurately determine aspirin effect in apparently healthy individuals by measuring levels of 11-dehydro thromboxane B₂ (11-dhTxB₂). High levels of 11-dhTxB₂, a metabolite of thromboxane — the target of aspirin therapy — heighten the risk of cardiovascular events, including stroke, myocardial infarction and cardiac death.

Millions of Americans take a daily aspirin to prevent heart attack or stroke but don't know if the aspirin is having the desired effect. The goal of aspirin therapy is to reduce levels of thromboxane in the blood, decreasing platelet stickiness and therefore reducing the chance of forming a blood clot.

Unlike other functional platelet tests that require freshly drawn blood that must be evaluated in five hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor's office. Physicians and laboratories interested in ordering the test can call 1-800-729-5661 x180, or email info@aspirinworks.com. More information is also available at www.aspirinworks.com.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com (Corporate website) and www.corgenix.net (Contract Services website).

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Corgenix Medical Corp.
Company Contact:
Corgenix Medical Corp.
William Critchfield, 303-453-8903
Senior VP and CFO
wcritchfield@corgenix.com
or
Media Contact:
Armada Medical Marketing
Dan Snyders, 303-623-1190 x230
Vice President and Public Relations Supervisor
dan@armadamedical.com

KEYWORDS:   United States  North America  Colorado  Texas

INDUSTRY KEYWORDS: